PROPANC BIOPHARMA, INC. Current Liabilities
PROPANC BIOPHARMA, INC. (PPCB) had Current Liabilities of $3.48 million as of 2026-03-31, per its S-1 filed 2026-07-17.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-17
- 2026-03-31: Liabilities, Current $3.48M.
- 2025-12-31: Liabilities, Current $3.62M.
- 2025-09-30: Liabilities, Current $3.57M.
- 2025-06-30: Liabilities, Current $5.58M.
| Period end | Liabilities, Current |
|---|---|
| 2026-03-31 | $3.48M S-1 · filed 2026-07-17 |
| 2025-12-31 | $3.62M S-1 · filed 2026-04-10 |
| 2025-09-30 | $3.57M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $5.58M S-1 · filed 2026-07-17 |
| 2025-03-31 | $4.34M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $4.15M 10-Q · filed 2025-02-14 |
| 2024-09-30 | $4.10M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.79M S-1 · filed 2026-07-17 |
| 2024-03-31 | $3.69M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $3.76M 10-Q · filed 2024-02-20 |
| 2023-09-30 | $3.13M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $3.16M 10-K · filed 2024-09-30 |
| 2023-03-31 | $3.06M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.99M 10-Q · filed 2023-02-10 |
| 2022-09-30 | $2.82M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.06M 10-K · filed 2023-09-28 |
| 2022-03-31 | $3.12M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $3.04M 10-Q · filed 2022-02-14 |
| 2021-09-30 | $2.37M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $3.08M 10-K · filed 2022-09-28 |
| 2021-03-31 | $3.03M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $3.65M 10-Q · filed 2021-02-12 |
| 2020-09-30 | $3.31M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $3.74M 10-K · filed 2021-09-28 |
| 2020-03-31 | $4.89M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $5.71M 10-Q · filed 2020-02-14 |
| 2019-09-30 | $4.72M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $4.40M 10-K · filed 2020-10-01 |
| 2019-03-31 | $3.67M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $4.62M 10-Q · filed 2019-02-14 |
| 2018-09-30 | $5.64M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $6.82M 10-K · filed 2019-10-15 |
| 2018-03-31 | $6.88M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $7.28M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $6.90M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $5.54M 10-K · filed 2018-09-17 |
| 2017-03-31 | $4.76M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $3.98M 10-Q · filed 2017-02-14 |
| 2016-09-30 | $1.99M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $2.94M 10-K · filed 2017-09-28 |
| 2016-03-31 | $5.14M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $4.86M 10-Q · filed 2016-02-16 |
| 2015-09-30 | $3.49M 10-Q · filed 2015-11-16 |
| 2015-06-30 | $3.68M 10-K · filed 2016-09-28 |
| 2015-03-31 | $2.16M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $1.93M 10-Q · filed 2015-02-17 |
| 2014-09-30 | $1.84M 10-Q · filed 2014-11-19 |
| 2014-06-30 | $1.52M 10-K · filed 2015-09-30 |
| 2014-03-31 | $1.17M 10-Q · filed 2014-05-20 |
| 2013-12-31 | $1.06M 10-Q · filed 2014-02-14 |
| 2013-09-30 | $1.26M 10-Q · filed 2013-11-14 |
| 2013-06-30 | $794.22K 10-K · filed 2014-10-14 |
| 2013-03-31 | $751.97K 10-Q · filed 2013-05-20 |
| 2012-12-31 | $655.52K 10-Q · filed 2013-02-20 |
| 2012-09-30 | $636.73K 10-Q · filed 2012-11-19 |
| 2012-06-30 | $584.19K 10-K · filed 2013-10-15 |
| 2012-03-31 | $482.23K 10-Q · filed 2012-05-21 |
| 2011-12-31 | $354.27K 10-Q/A · filed 2012-03-07 |
| 2011-06-30 | $306.85K 10-K · filed 2012-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |